Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.00M | $7.58M | $0.00 | $17.1K | $437K | $1.16M | $1.71M | $2.54M | $2.50M | $2.98M |
| Revenue growth | — | 152.8% | -100.0% | — | 2460.3% | 165.6% | 47.1% | 48.8% | -1.6% | 19.0% |
| Operating income | -$47.4M | -$3.57M | -$7.28M | -$12.9M | -$13.9M | -$5.75M | -$6.72M | -$4.52M | -$4.20M | -$2.83M |
| Operating margin | -1581.0% | -47.1% | — | -75511.7% | -3189.8% | -495.1% | -393.6% | -177.8% | -168.2% | -95.2% |
| Net income | -$54.2M | -$3.60M | -$7.30M | -$12.8M | -$10.9M | -$5.65M | -$6.55M | -$4.13M | -$3.96M | -$2.68M |
| Net margin | -1806.9% | -47.4% | — | -74856.6% | -2493.1% | -486.4% | -383.9% | -162.8% | -158.4% | -90.1% |
| EPS (diluted) | -$7.84 | -$0.41 | -$9.66 | -$6.33 | -$1.70 | -$0.55 | -$4.61 | -$2.71 | -$2.57 | -$1.58 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.79M | $1.49M | -$6.46M | -$6.40M | -$4.27M | -$4.74M | -$4.65M | -$4.11M | -$2.82M | -$2.29M |
| Capital expenditures | $16.8K | $9.26K | $0.00 | — | — | — | — | — | — | — |
| Free cash flow | -$8.80M | $1.48M | -$6.46M | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $4.11M | $5.60M | $638K | $10.4M | $11.5M | $18.2M | $13.1M | $8.98M | $6.17M | $7.88M |
| Total assets | $21.0M | $19.2M | $14.4M | $21.5M | $13.2M | $19.8M | $14.7M | $10.6M | $6.90M | $8.36M |
| Total liabilities | $4.80M | $4.86M | $4.52M | $4.33M | $964K | $1.42M | $1.07M | $810K | $894K | $968K |
| Shareholders' equity | $16.2M | $14.3M | $9.91M | $17.2M | $12.2M | $18.4M | $13.6M | $9.80M | $6.01M | $7.40M |
| Retained earnings | -$142M | -$146M | -$153M | -$166M | -$177M | -$183M | -$189M | -$193M | -$197M | -$200M |
| Shares (wtd avg diluted) | 4.59M | 8.72M | 9.40M | 6.07M | 8.75M | 10.3M | 1.42M | 1.53M | 1.54M | 1.70M |
Every figure is extracted from Xenetic Biosciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.